

Will Obama Name This Big Pharma Insider as Head of the FDA?

'Too close for comfort' to the drug industry

By [Christina Sarich](#)

Global Research, October 22, 2015

[Natural Society](#)

Region: [USA](#)

Theme: [Science and Medicine](#)

Americans already pay more for pharmaceutical drugs than almost any other nation, and we also [take the lion's share of them](#), though our overall health as a nation is relatively poor. Do we really need a Big Pharma insider as the chief of the US Food and Drug Administration (USFDA)? That is just what may happen.

President Obama [has nominated Dr. Robert Califf](#), a doctor described as “the ultimate industry insider” to this position. [According to](#) the New York Times, Dr. Califf “has deeper ties to the pharmaceutical industry than any F.D.A. commissioner in recent memory.” He has an extensive record of close collaboration with pharmaceutical giants, and recently described regulation as a “barrier,” not a safeguard for public health.

While he donates his Big Pharma speaking and consulting fees to charity, his lucrative salary at Duke University is directly supported by companies like Merck, Novartis, and Eli Lilly. Duke University receives more than 60% of its funding from the pharmaceutical industry. [1]

So why would Obama appoint the [ultimate industry insider](#) to the FDA? I'm sure you can think of a few reasons if you've been reading Natural Society for any length of time. Why would the leader of the nation appoint someone who is getting kickbacks and other financial support from over 20 different pharmaceutical companies – all of which Califf has admitted to.

If the senate allows Obama's nomination, Califf will steer one of the biggest agencies in government – one that accounts for about 25 cents of every dollar American's spend on drugs – and that amounts to *billions* annually.

One of the FDA's recent allowances for Big Pharma which would likely only get worse under the 'rule' of an insider like Califf is [S 3187](#), a bill which is primarily concerned with increasing the pay-to-play administrative fees; in other words, the FDA is going to charge those who contract with them more while at the same time shortening the time it takes to get [all pharmaceuticals approved](#).

That means more fast-tracking for more drugs that harm and impair the public at high costs. Need an example of some recent ones? Look [here for a listing](#) of over 35 that had to be pulled from shelves after FDA approval.

This savvy insider, Califf, also helped the medical industry find and pay faculty for 'regulatory consulting.' According to the Intercept:

“Ethics forms and business incorporation documents show that from 2006 through this year, Califf served as a board member and consultant to [Faculty Connection LLC](#). The company boasts that its team of “practicing university-based physicians and researchers” provides “regulatory consulting,” including expertise in FDA briefing reviews and other regulatory submissions to the agency.”

AIDS healthcare Foundation (AHF), which has criticized FDA Commissioner nominee Dr. Robert Califf as ‘too close for comfort’ to the drug industry, [has called on](#) President Barack Obama to immediately withdraw Dr. Califf’s name from consideration for the post as head of the FDA after news broke that Califf previously ran an academic headhunting company that had deep ties to the drug industry and whose primary mission appears to be have been to avoid or lessen government regulation of the industry.

There is now a petition for US citizens to ask Obama to remove the nomination as well.

Notes:

[1] [Reuters](#)

[US News Health](#) (Featured image source)

The original source of this article is [Natural Society](#)
Copyright © [Christina Sarich](#), [Natural Society](#), 2015

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Christina Sarich](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca